25,100 Shares in Insulet Co. (NASDAQ:PODD) Bought by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS acquired a new position in Insulet Co. (NASDAQ:PODD) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,100 shares of the medical instruments supplier’s stock, valued at approximately $6,553,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. AXQ Capital LP acquired a new stake in shares of Insulet in the fourth quarter valued at about $725,000. Sei Investments Co. increased its holdings in Insulet by 20.0% in the fourth quarter. Sei Investments Co. now owns 72,166 shares of the medical instruments supplier’s stock valued at $18,840,000 after buying an additional 12,041 shares in the last quarter. Mizuho Securities USA LLC boosted its stake in shares of Insulet by 46.2% during the 4th quarter. Mizuho Securities USA LLC now owns 6,648 shares of the medical instruments supplier’s stock worth $1,736,000 after acquiring an additional 2,101 shares in the last quarter. iA Global Asset Management Inc. grew its holdings in shares of Insulet by 131.1% in the 4th quarter. iA Global Asset Management Inc. now owns 4,756 shares of the medical instruments supplier’s stock worth $1,242,000 after acquiring an additional 2,698 shares during the period. Finally, Teacher Retirement System of Texas grew its holdings in shares of Insulet by 1.0% in the 4th quarter. Teacher Retirement System of Texas now owns 18,328 shares of the medical instruments supplier’s stock worth $4,785,000 after acquiring an additional 187 shares during the period.

Analyst Upgrades and Downgrades

A number of research firms have commented on PODD. Canaccord Genuity Group boosted their target price on Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Citigroup lifted their price target on Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Wells Fargo & Company increased their price objective on shares of Insulet from $305.00 to $322.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. TD Cowen raised their target price on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a report on Friday, January 3rd. Finally, Stifel Nicolaus upped their price target on shares of Insulet from $245.00 to $293.00 and gave the company a “hold” rating in a report on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, Insulet presently has an average rating of “Moderate Buy” and an average price target of $292.06.

Insulet Stock Performance

Insulet stock opened at $272.71 on Wednesday. The stock has a fifty day moving average price of $272.27 and a 200 day moving average price of $258.19. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46. The firm has a market capitalization of $19.15 billion, a P/E ratio of 47.10, a PEG ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. Equities research analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current year.

Insider Activity

In related news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.47% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.